Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
COLORADO SPRINGS, Colo., Feb. 09, 2016 -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2015 fourth quarter financial results after market close on Thursday, February 25, 2016. Company management will host an investment-community conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, February 25 to discuss those results and to answer questions.
Individuals interested in listening to the conference call may do so by dialing (877) 561-2747 for domestic callers, or (973) 409-9689 for international callers (Conference ID: 39913305), or from the webcast on the investor relations section of the Company’s website at: www.spectranetics.com. The webcast will be available on the Company’s website for 14 days following the completion of the call.
About Spectranetics
Spectranetics develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt® scoring balloon used in both peripheral and coronary procedures and Stellarex™ drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen, Sr. Director of Finance [email protected] (719) 447-2292 Jamar Ismail [email protected] (415) 513-1282
